Pharmacogenetics of morphine: Potential implications in sickle cell disease
โ Scribed by Deepika S. Darbari; Caterina P. Minniti; Sohail Rana; John van den Anker
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 91 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Morphine is frequently used to treat painful episodes associated with sickle cell disease (SCD) but may fail to provide adequate analgesia in many patients. This concise review focuses on unique disease related changes in physiologic variables associated with SCD that impacts pharmacokinetics and pharmacodynamics of morphine and may contribute to the variability in analgesia. Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonopioid system (COMT gene) can alter the efficacy of morphine. Am. J. Hematol., 2008. ยฉ 2007 WileyโLiss, Inc.
๐ SIMILAR VOLUMES
## Abstract Changes in several components of the clotting system are well documented in sickle cell disease (SCD) patients. However, whether the global hemostatic potential of these patients is altered is still unclear. Calibrated automated thrombogramยฎ method of thrombin generation (TG) was used t
Frequency of painful episodes in sickle-cell disease is considered to be related to clinical severity and possibly to other aspects of the disease. Measurements of frequency often include only hospital-related or more severe, longer-lasting episodes. Since painful episodes, however, may regularly oc